Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial
Open accessThe DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Xpert® MTB/RIF (Xpert) has high sensitivity for diagnosing tuberculosis (TB) compared to sputum-smear microscopy (smear) and can reduce time-to-diagnosis, time-to-treatment and potentially unfavorable patient-level treatment outcome. METHODS: People living with HIV (PLHIV) initiating antiretroviral therapy at 22 HIV clinics were enrolled and underwent systematic screening for TB (August 2012-November 2014). GeneXpert instruments were deployed following a stepped-wedge design at 13 centers from October 2012-June 2013. Treatment outcomes classified as an unfavorable outcome (died, treatment failure or loss-to-follow-up) or favorable outcome (cured and treatment completed). To determine outcome, smear was performed at month 5 or 6. Empiric treatment was defined as initiating treatment without/before receiving TB-positive results. Adjusting for intra-facility correlation, we compared patient-level treatment outcomes between patients screened using smear (smear arm)- and Xpert-based algorithms (Xpert arm). RESULTS: Among 6041 patients enrolled (smear arm, 1816; Xpert arm, 4225), 256 (199 per 2985 and 57 per 1582 person-years of follow-up in Xpert and smear arms, respectively; adjusted incidence rate ratio, 9.07; 95% confidence interval [CI]: 4.70-17.48; p < 0.001) received TB diagnosis and were treated. TB treatment outcomes were available for 203 patients (79.3%; Xpert, 157; smear, 46). Unfavorable outcomes were reported for 21.7% (10/46) in the smear and 13.4% (21/157) in Xpert arm (adjusted hazard ratio, 1.40; 95% CI: 0.75-2.26; p = 0.268). Compared to smear, in Xpert arm median days from sputum collection to TB treatment was 6 days (interquartile range [IQR] 2-17 versus 22 days [IQR] 3-51), p = 0.005; patients with available sputum test result had microbiologically confirmed TB in 59.0% (102/173) versus 41.9% (18/43), adjusted Odds Ratio [aOR], 2.00, 95% CI: 1.01-3.96, p = 0.048). In smear arm empiric treatment was 68.4% (39/57) versus 48.7% (97/199), aOR, 2.28, 95% CI: 1.24-4.20, p = 0.011), compared to Xpert arm. CONCLUSIONS: TB treatment outcomes were similar between the smear and Xpert arms. However, compared to the smear arm, more patients in the Xpert arm received a TB diagnosis, had a microbiologically confirmed TB, and had a shorter time-to-treatment, and had a lower empiric treatment. Further research is recommended to identify potential gaps in the Botswana health system and similar settings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02538952. Retrospectively registered on 2 September 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The shortest time between steps was two weeks, observed by Josee Uwamariya (2021) and Tefera Agizew (2019) (69, 104).”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Theron, G., Zijenah, L., Chanda, D., Clowes, P., Rachow, A., Lesosky, M., Bara, W., Mungofa, S., Pai, M., Hoelscher, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62073-5 · Cited by 433
Gupta, R. K., Lucas, S. B., Fielding, K. L., & Lawn, S. D. (2015) · AIDS · doi:10.1097/qad.0000000000000802 · Cited by 371
Churchyard, G. J., Stevens, W. S., Mametja, L. D., McCarthy, K. M., Chihota, V., Nicol, M. P., Erasmus, L. K., Ndjeka, N. O., Mvusi, L., Vassall, A., et al. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00100-x · Cited by 209
Self-citationAnsari, N. A., Kombe, A. H., Kenyon, T. A., Hone, N. M., Tappero, J. W., NYIRENDA, S., BINKIN, N. J., & Lucas, S. B. (2002) · PubMed · Cited by 205
Self-citationBadje, A., Moh, R., Gabillard, D., Guéhi, C., Kabran, M., Ntakpé, J.-B., Carrou, J. L., Kouame, G. M., Ouattara, E., Messou, E., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30372-8 · Cited by 169
Theron, G., Peter, J., Dowdy, D., Langley, I., Squire, S. B., & Dheda, K. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70360-8 · Cited by 162
Cox, H. S., Mbhele, S., Mohess, N., Whitelaw, A., Muller, O., Zemanay, W., Little, F., Azevedo, V., Simpson, J., Boehme, C. C., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001760 · Cited by 145
Durovni, B., Saraceni, V., van den Hof, S., Trajman, A., Cordeiro-Santos, M., Cavalcante, S., Menezes, A., & Cobelens, F. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001766 · Cited by 137 · cited 2×
“On the basis of its accuracy, shorter turnaround time, and potentially reduced loss-to-follow-up, Xpert MTB/RIF may results in earlier diagnosis and anti-TB treatment initiation to improve patient-level clinical outcomes [7, 9, 10].”
BackgroundResultYoon, C., Cattamanchi, A., Davis, J. L., Worodria, W. O., den Boon, S., Kalema, N., Katagira, W., Kaswabuli, S., Miller, C. R., Andama, A. O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048599 · Cited by 97
Shah, S., Demissie, M., Lambert, L., Ahmed, J., Leulseged, S., Kebede, T., Melaku, Z., Mengistu, Y., Lemma, E., Wells, C. D., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318196761c · Cited by 85
Trajman, A., Durovni, B., Saraceni, V., Menezes, A., Cordeiro‐Santos, M., Cobelens, F. G. J., & van den Hof, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123252 · Cited by 54 · cited 4×
“Xpert MTB/RIF has a high sensitivity for diagnosing TB among people living with HIV (PLHIV) compared to sputum-smear microscopy (smear), and can potentially reduce time-to-diagnosis and time-to-treatment leading to improved TB treatment outcomes [7, 8].”
BackgroundMethodResultInfluentialCalligaro, G., Theron, G., Khalfey, H., Peter, J., Meldau, R., Matinyenya, B., Davids, M., Smith, L., Pooran, A., Lesosky, M., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00198-8 · Cited by 52
Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis
Lawn, S. D., Nicol, M. P., & Corbett, E. L. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71049-7 · Cited by 28
Agizew, T., Boyd, R., Ndwapi, N., Auld, A. F., Basotli, J., Gwebe-Nyirenda, S., Tedla, Z., Mathoma, A., Mathebula, U., Lesedi, C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183237 · Cited by 23
Self-citationAuld, A. F., Agizew, T., Pals, S. L., Finlay, A. M., Ndwapi, N., Boyd, R., Alexander, H. L., Mathoma, A., Basotli, J., Gwebe-Nyirenda, S., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1905-4 · Cited by 22
Self-citation
Research works printed but not linked: 10
- Botswana S Botswana Aids impact survey IV (BAIS IV) 2013
- Botswana National Tuberculosis Program (BNTP) Manual, Ministry of Health, Botswana 2011
- Fielding K, Mccarthy K, Ginindza S, Chihota V, Charalambous S, Churchyard G, et al, A grant. Treatment outcome participant in the XTEND trial. Abstract OA-386-05. 46th Conference on Lung Health, Liverpool, Cape Town, South Africa 2–6 December 2015.
- World Health Organization Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) 2013
- StataCorp Stata statistical software: release 14 2015 College Station StataCorp LP
- CONSORT Checklist of information to include when reporting a randomised trial 2010
- Auld A Agizew T Mathoma A Boyd R Date A Pals S Effect of TB screening and retention interventions on early ART mortality in Botswana. Oral abstract 31, 25th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts 2018
- Stop TB Partnership’s New Diagnostics Working Group/World Health Organization Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics 2009 Geneva World Health Organization
- The World health organization Latent tuberculosis infection Updated and consolidated guidelines for programmatic Management, WHO/CDS/TB/2018.4 2018 30277688
- Sun A, Denkinger C, Dowdy D. Understanding the diagnostic cascade of tuberculosis: insight from a transmission model. Abstract OAP-314-31. 45th Conference on Lung Health, Barcelona, Spain, 28 October – 1 November 2014.
Cited by
Zifodya, J. S., Kreniske, J. S., Schiller, I., Kohli, M., Dendukuri, N., Schumacher, S. G., Ochodo, E. A., Haraka, F., Zwerling, A. A., Pai, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub5 · Cited by 179
Lee, J. H., Garg, T., Lee, J., McGrath, S., Rosman, L., Schumacher, S., Benedetti, A., Qin, Z., Gore, G. C., Pai, M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07855-9 · Cited by 39
Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis
Haraka, F., Kakolwa, M. A., Schumacher, S. G., Nathavitharana, R. R., Denkinger, C. M., Gagneux, S., Reither, K., & Ross, A. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012972.pub2 · Cited by 53
“Similar findings were reported in a recent review, in which Xpert MTB/RIF was shown to be superior for tuberculosis bacteriological confirmation, in a subset of seven of the nine studies that we included (Agizew 2019b).”
BackgroundMethodResultInfluentialA Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV
Kulkarni, V., Queiroz, A. T. L., Sangle, S., Kagal, A., Salvi, S., Gupta, A., Ellner, J. J., Kadam, D., Rolla, V. C., Andrade, B. B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631165 · Cited by 25
“(5) Rutgers New Jersey Medical School IRB, USA.”
BackgroundSvadzian, A., Daniels, B., Sulis, G., Das, J., Daftary, A., Kwan, A. T., Das, V., Das, R., & Pai, M. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100152 · Cited by 10
Metadata
- Authors
- Agizew, T., Chihota, V., Nyirenda, S., Tedla, Z., Auld, A. F., Mathebula, U., Mathoma, A., Boyd, R., Date, A., Pals, S. L., Lekone, P., & Finlay, A.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of the Witwatersrand (ZA)
- Corresponding author
- Agizew, Tefera
- ORCID
- Venue
- BMC Infectious Diseases
- Published
- 2019-12
- Volume
- 19
- Issue
- 1
- Pages
- 1058-1058
- ISSN
- 1471-2334 (ISSN-L)
- PMC
- PMC6915885
- OpenAlex
- W2994745681
- Cited by
- 17
- References
- 18
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2022: 2 · 2021: 7
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 15 d)
- Locations
- BMC Infectious Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Greater South Information System
- Funders
- This research has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention. (Not Applicable)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- tuberculosis, HIV, Xpert MTB/RIF, sputum smear microscopy, tuberculosis treatment outcomes, tuberculosis screening, tuberculosis diagnosis, treatment failure, loss to follow-up, time to treatment, Botswana
- MeSH terms
- Data Accuracy, Adult, Botswana, Female, Follow-Up Studies, Humans, Male, Mass Screening, Microscopy, Mycobacterium tuberculosis, Prospective Studies, Sensitivity and Specificity, Sputum, Tuberculosis, HIV Infections, Treatment Outcome, Nucleic Acid Amplification Techniques, Lost to Follow-Up, Time-to-Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
